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Abstract
Although rare in its idiopathic form, pulmonary arterial hypertension (PAH) is not uncommon in
association with various associated medical conditions, most notably connective tissue disease (CTD). In
particular, it develops in approximately 10% of patients with systemic sclerosis and so these patients are
increasingly screened to enable early detection. The response of patients with systemic sclerosis to PAH-
specific therapy appears to beworse than in other forms of PAH. Survival in systemic sclerosis-associated
PAH is inferior to that observed in idiopathic PAH. Potential reasons for this include differences in age,
the nature of the underlying pulmonary vasculopathy and the ability of the right ventricle to cope with
increased afterload between patients with systemic sclerosis-associated PAH and idiopathic PAH, while
coexisting cardiac and pulmonary disease is common in systemic sclerosis-associated PAH. Other forms
of connective tissue-associated PAH have been less well studied, however PAH associated with systemic
lupus erythematosus (SLE) has a better prognosis than systemic sclerosis-associated PAH and likely
responds to immunosuppression.
Introduction
Pulmonary hypertension is defined as a mean pulmonary
arterial pressure (mPAP) of ≥25 mmHg when measured at
right heart catheterization [1]. Current classification
describes five main groups with shared clinical and
pathophysiological characteristics (Figure 1): group 1,
PAH; group 2, pulmonary hypertension associated with
left heart disease; group 3, pulmonary hypertension
associatedwith lung disease; group 4, chronic thromboem-
bolic pulmonary hypertension (CTEPH); and group 5,
miscellaneous with unclear mechanisms [2]. Although
PAH is rare in the general population (idiopathic PAH
having an incidence of 1–2/million/year) [3] it is more
common in several associated conditions, most noticeably
CTD. As a consequence of the high prevalence of both left
heart disease and interstitial lung disease in CTD, the
accurate diagnosis of PAH is particularly challenging.
Although PAH in other forms of CTD (CTD-PAH) will
be briefly discussed, PAH is most commonly seen in
association with systemic sclerosis and is the main focus of
this review. In particular the differences between systemic
sclerosis with PAH and idiopathic PAH will be explored.
Systemic sclerosis
Epidemiology
The prevalence of systemic sclerosis within the general
population ranges from 80/million in the UK [4] to
240/million in theUSA [5]. Prospective right heart catheter-
based studies have observed a prevalence of PAH in
patients with systemic sclerosis of 7.8–12% while a recent
meta-analysis calculated the prevalence to be 9% [6,7]. The
French Itiner-Air group observed an annual incidence of
PAH in patients with systemic sclerosis of 0.61% [8].
Pathogenesis
Systemic sclerosis-PAH is characterized by intimal hyper-
plasia, medial hypertrophy and adventitial fibrosis as in
other forms of PAH although, compared to idiopathic
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PAH, a lower number of plexiform lesions are observed
[9]. Recent histological data suggest a surprisingly high
involvement of pulmonary venules, although the propor-
tion of patients with clinically overt pulmonary veno-
occlusive disease (PVOD) is lower [7,9,10]. Mutations
in bone morphogenetic receptor type 2 (BMPR-2), which
are well described in idiopathic and heritable PAH, have
not been demonstrated in systemic sclerosis-PAH. An
increased frequency of a polymorphism in the gene coding
for endoglin, a component of the transforming growth
factor beta (TGF-B) receptor complex, which is associated
with hereditary haemorrhagic telangectasia and has
been identified in patients with idiopathic PAH [11], has
been recently identified in patients with systemic sclerosis-
PAH [12].
Systemic sclerosis is an autoimmune condition and, as
such, it seems likely that autoimmunity and inflamma-
tion will play an important role in the development of
PAH. In support of this hypothesis, lymphocytes,
macrophages and leucocytes have been identified in
pulmonary arterial vascular lesions in systemic sclerosis-
PAH [10]. The association between several auto-
antibodies and the presence of isolated systemic sclerosis
are well recognized, including anticentromere, anti-
topoisomerase-1 (SCl-70), anti-RNA-polymerase-III and
anti-Th/To antibodies. However, their exact role in the
pathogenesis of PAH is unclear [13]. Studies in systemic
sclerosis patients without PAH have identified high
levels of molecules associated with endothelial cell
activation and apoptosis (VCAM) and angiogenesis
(vascular endothelial growth factor [VEGF]), which
would be consistent with the risk of subsequent PAH
development [14,15]. Anti-fibroblast IgG from sera of
systemic sclerosis patients has been shown to activate
normal fibroblasts, and it is hypothesized that fibroblast
activationmay lead to the induction of collagen synthesis,
which may promote subsequent vascular remodeling
[16]. Becker et al. have recently reported elevated levels
of stimulating anti-endothelin receptor type A antibodies
Figure 1. Current PH classification system
Patients with pulmonary hypertension (PH) in association with connective tissue disease may sit in group 1 (pulmonary arterial hypertension), group 2
(PH associated with left heart disease) or group 3 (PH associated with lung disease) while group 4 (chronic thromboembolic pulmonary hypertension) disease
must also be excluded. Reproduced with permission [77]
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and anti-angiotensin receptor type-1 antibodies in sys-
temic sclerosis-PAH and CTD-PAH when compared with
idiopathic PAH [17]. Serum levels of both antibodies were
prognostic, despite a lack of correlation with pulmonary
haemodynamics, and also predicted the development of
PAH in a separate cohort of systemic sclerosis patients
without PAH at baseline.
Risk factors
The classical systemic sclerosis patient considered to be at
high-risk of developing PAH has limited cutaneous disease
of >5 years duration, a low lung gas transfer (DLCO) and is
anticentromere antibody positive [18–21]. More recent
data have challenged some of these suppositions. A recent
studyof 78 consecutively diagnosed systemic sclerosis-PAH
patients reported the onset of PAH <5 years from the onset
of limited cutaneous systemic sclerosis in 55% of patients
[22]. Similarly, more recent studies have suggested that
PAH is almost as common in diffuse disease [17,23]. A
reduced and falling gas transfer (DLCO) is common in
patients with systemic sclerosis-PAH, with amean DLCO of
52% predicted 4.5 years prior to the diagnosis of PAH,
comparedwith ameanDLCOof 80%predicted innon-PAH
systemic sclerosis patients [19,24]. Interestingly, patients
with systemic sclerosis-PAHhave lowerDLCO than patients
with idiopathic PAH, despite having less severe pulmonary
haemodynamics at presentation (discussed below) [25].
As well as the recognized risk of PAH in patients with
anticentromere antibody, associations between the pre-
sence of anti-RNA-polymerase-III and anti-Th/To antibo-
dies and PAH have also been reported [13].
Prognosis
Several large registries have reported survival in systemic
sclerosis-PAH over recent years (Table 1): the UK national
registry enrolled 259 incident patients and observed 1-
and 3-year survival of 78% and 47% [26]; the REVEAL
registry enrolled 399 predominantly prevalent cases and
observed a 1-year survival of 82% [20]; the ASPIRE
registry enrolled 156 incident patients and observed a
3-year survival of 52% [25]; the French Registry enrolled
85 incident patients and observed 1- and 3-year survival
of 90% and 56% [27]; and the PHAROS registry enrolled
131 incident patients (with a high proportion in World
Health Organisation [WHO] Functional Class [FC]
I and II) and observed 1- and 3-year survival of 93%
and 75% [28]. The different outcomes reported are likely
to be impacted by differences in patient characteristics
(e.g., in the PHAROS study a high proportion were in
WHO FC I and II, reflecting a higher proportion of
patients identified by screening). Lefevre et al. recently
performed a meta-analysis to adjust for these differences,
and observed 1- and 3-year survival of 81% and 52% [29].
Prognostic factors identified at multivariate analysis have
also differed between studies, but have included age
[26,28], male gender [26,28], DLCO [26,28], functional
class [26,28], pulmonary vascular resistance [21], pul-
monary capacitance [21], stroke volume index [21] and
estimated glomerular filtration rate [21].
It is unclear whether survival in systemic sclerosis-PAH has
improved with the introduction of PAH-specific therapies.
Historical case series prior to the widespread availability of
PAH-specific therapies reported median survival rates of
around one year, but are limited by their extremely small
size [30]. Rubenfire et al. recently reported no difference in
survival in patients diagnosed before 2002 (when only
prostacyclin was available) than in patients diagnosed
from 2002 onwards (when oral therapies were made
available), whereas survival in idiopathic PAH did
improve over the same period [31]. Similarly, in their
meta-analysis Lefevre et al. also found no relationship
between survival and years of enrollment of each study,
which may also suggest no progressive improvement in
survival over the last decade [29].
Detection
Given the relatively high prevalence of PAH in systemic
sclerosis, active screening of patients is advocated [32].
Humbert et al. demonstrated that patients identified with
systemic sclerosis-PAH via a screening programme had
milder disease and superior survival than those patients
who presented with symptomatic disease [33]. Although
Table 1. Prognosis of SSc-PAH in selected major registries














UK [26] 2009 259 64 100 16/68/16 42 715 78 47
REVEAL [20] 2010 399 62 18 25/60/15 45 768 82 n/a
ASPIRE [25] 2012 156 66 100 19/67/14 43 678 82 52
French [27] 2013 85 65 100 21/67/12 41 680 90 56
PHAROS [28] 2014 131 60 100 56/38/6 36 448 93 75
Age and haemodynamic data presented as mean.
Abbreviaitons: mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; SSc, systemic sclerosis;
WHO FC, World Health Organisation Functional Class
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patients with mildly symptomatic disease have been
shown to benefit from PAH therapy, the contribution
lead-time bias plays in the superior survival of screened
patients is still unclear [34]. Current European Respiratory
Society (ERS)/European Society of Cardiology (ESC)
guidelines recommend annual screening with echocardio-
graphy in patients with systemic sclerosis [32]. Mukerjee
et al. demonstrated a DLCO of <55% to have high
sensitivity for pulmonary hypertension, but no threshold
for either echocardiography-derived systolic pulmonary
artery pressure or DLCO could be identified which could
confidently exclude pulmonary hypertension [35]. The
recently published multicentre DETECT study enrolled
466 systemic sclerosis patients enriched for an increased
risk of PAH (>3 years from diagnosis of systemic sclerosis
with DLCO <60%) and derived a score based on 6 non-
echocardiographic variables (forced vital capacity [FVC])
% predicted/ DLCO % predicted, present/past telengecta-
sia, anticentromere antibody, N-terminal pro-brain
natriuretic peptide (NT-proBNP), serum urate and right
axis deviation on electrocardiogram (ECG) to guide
whether or not an echocardiogram is subsequently
required [36]. A second score based on right atrial area
and tricuspid regurgitant velocity is then added to the first
score to produce a total score that determines whether
right heart catheterisation is required. The DETECT
protocol resulted in more patients in this enriched cohort
being referred for right heart catheterisation but resulted in
less false negatives than an approach using echocardio-
graphy alone (4% versus 29%). There are important
limitations to the DETECT approach: the protocol has not
been validated in a separate cohort, has not been studied
in patients <3 years from diagnosis of systemic sclerosis or
with DLCO >60% and importantly has not been compared
with a more holistic approach to identifying patients with
systemic sclerosis-PAH currently used in many centers,
which incorporates echocardiography, DLCO and symp-
toms to identify patients requiring right heart catheterisa-
tion. Furthermore, it is not clear how practical the DETECT
algorithmwill be inwidespread clinical practice, especially
in terms of accurate measurement of right atrial area and
availability of NT-proBNP assays.
A proportion of patients undergoing screening will be
found to have borderline mean pulmonary arterial
pressures of 21-24 mmHg at right heart catheterization.
A recent study of 228 patients in the Royal Free Hospital,
London, observed progression to PAH in 31% of such
patients at subsequent right heart catheterization, suggest-
ing that patients with borderline pressures require careful
monitoring [37]. Bae et al. repeated right heart catheterisa-
tion in 11/28 patients with the same borderline pulmonary
pressures and found that 6/11 had developed resting pul-
monary hypertension after a mean period of 14 months
[38]. Of note, associated interstitial lung disease and
restrictive spirometry was more common in those patients
with borderline pressure than in those with normal
pressure.
Exercise may have a role in the earlier identification of
patients with pulmonary vasculopathy in connective
tissue disease, with differential patterns of gas exchange
on non-invasive exercise testing distinguishing pul-
monary vascular disease from left heart disease in
systemic sclerosis [39]. Patients with elevation of mPAP
>30 mmHg on exercise appear to be at risk of
developing PAH with 19% of patients developing
PAH at rest in the UK national CTD-PAH registry [26].
Additional evidence demonstrating improved haemo-
dynamics and exercise capacity in response to the
endothelin-1 receptor antagonist, ambrisentan, in
patients with exercise-induced systemic sclerosis-
pulmonary hypertension further suggests this is a
precursor to PAH [40]. The normal response in mPAP
at exercise in patients without PAH at rest is not
known [41] and so routine exercise at right heart
catheterization is not currently recommended [1].
Treatment
Current PAH-specific therapies target 3 pathways
(prostacyclin, endothelin-1 and nitric oxide) [42].
Several subgroup analyses of CTD-PAH patients
enrolled in the pivotal randomized controlled trials
(RCTs) have been published which, apart from one
exception [43], suggest a less marked response to PAH
therapy in CTD-PAH. It is possible that this may be
partly due to the fact that the six minute walk distance
(6MWD), which has been used as the primary endpoint
in the majority of RCTs of PAH-specific therapies, may
particularly be affected by age and musculoskeletal
pathology in patients with CTD.
Prostanoids
An unblinded RCT of continuous intravenous epoproste-
nol (which is administered by a portable pump via an
indwelling central line), involving 111 patients with
systemic sclerosis-PAH, observed a significant improve-
ment in mean 6MWD of 46 metres following 12 weeks of
treatment, while patients receiving placebo experienced a
mean decrease of 48 metres (P<0.05) [43]. Due to its
much longer half-life, the prostacyclin analogue trepros-
tinil can be administered via continuous subcutaneous
infusion, thus removing the risk of line infection. Ninety
patients with CTD-PAH (including 45 patients with
systemic sclerosis-PAH) from the original RCT (which
also included 270 patients with idiopathic PAH and 109
patients with congenital heart disease) were analysed
separately [44]. Unlike in the original study, the between
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treatment group’s difference in median 6MWD did not
reach statistical significance (+25 metres, P=0.06) in the
CTD-PAH group. Furthermore, improvements in the
secondary endpoints of Borg dyspnoea score, mean right
atrial pressure, mean pulmonary artery pressure, and
mixed venous oxygen saturation seen in the original study,
were not observed in the subgroup analysis.
Endothelin-1 receptor antagonist
Bosentan, an endothelin-1 receptor antagonist, was
studied in an RCT involving 213 PAH patients [45]. In
the 150 idiopathic PAH patients, the 6MWD increased
by 46metres after 16 weeks of therapy, while it decreased
by 5 metres in the placebo group (P<0.05). A different
picture was seen in patients with systemic sclerosis-PAH;
among the 14 patients in the placebo group there was a
decline of 40 metres, while in the 33 patients receiving
active therapy deterioration was prevented with an
improvement of 3 metres (P=not significant). No RCT
data specifically on CTD-PAH have been published to
date for the other currently available endothelin-1
receptor antagonists, ambrisentan and macitentan.
Phosphodiesterase-5 inhibitors
A subgroup analysis of the 84 patients with CTD-PAH
(including 50 patients with systemic sclerosis) who were
included in the SUPER-1 trial of sildenafil was subse-
quently published [46,47]. In the original study of
278 patients, in which patients received 20 mg, 40 mg or
80 mg three times a day, the mean placebo-controlled
treatment effects on 6MWDwere +45 metres, +46 metres
and +50 metres after 12 weeks. Direct comparison is
difficult especially since patients with SLE may have a
greater response to treatment. However, the treatment
effect in the subgroup analysis tended to be smaller, with
the 6MWD increasing by +42 metres, +36 metres and
+15 metres in patients receiving the three different doses.
Comparison of systemic sclerosis-PAH with
idiopathic PAH
Survival in systemic sclerosis-PAH is significantly worse
than in idiopathic PAH, despite less severe pulmonary
haemodynamics (Figure 2) [20,25,48–50]. There are
several potential reasons for this disconnect between
pulmonary hypertension severity and outcome (Table 2).
Age
Patients with systemic sclerosis-PAH are up to a decade
older than patients with idiopathic PAH at diagnosis
[25]. Age is an independent prognostic factor in systemic
sclerosis-PAH [26] and was also found to be an
independent predictor of mortality in a study involving
50 systemic sclerosis-PAH patients and 41 idiopathic
PAH patients [50].
Pulmonary vasculopathy
Dorfmuller et al. studied lung tissue samples from
8 patients with various forms of CTD-PAH and com-
pared them with 29 idiopathic PAH patients [10].
Obstructing lesions in pulmonary veins and venules
were seen in 75% of the CTD-PAH patients and 17% of
the idiopathic PAH patients (P<0.05). Overbeek et al.
subsequently studied lung tissue samples from 8 systemic
sclerosis-PAH and 11 idiopathic PAH patients [51]. They
observed plexogenic lesions in all the idiopathic PAH
patients and none of the systemic sclerosis-PAH patients.
Furthermore, they observed pulmonary vein and venule
fibrosis in all of the systemic sclerosis-PAHpatients (with a
pattern consistent with PVOD in 50%) and only 3 of the
idiopathic PAH patients. Gunther et al. observed at least
2 radiographic signs consistent with PVOD on high
resolution computerized tomography (CT) imaging (cen-
trilobular ground glass abnormalities, septal lines and
lymphadenopathy) in 16/26 patients with systemic
Figure 2. Survival of IPAH and SSc-PAH in the ASPIRE registry
Adapted with permission [25]. Abbreviations: IPAH, idiopathic pulmonary
arterial hypertension; PAH, pulmonary arterial hypertension; SSc, systemic
sclerosis
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sclerosis-PAH [52]. Furthermore, 8 of those 16 patients
developed pulmonary oedema on commencement of
PAH-specific therapy. Clinical experience in centres treat-
ing large numbers of patients with systemic sclerosis-PAH
would suggest that frank PVOD is significantly less
common than this. Nevertheless, idiopathic PVOD is
associated with an exceedingly poor survival and, taken
together, these data suggest that a PVOD-component in a
proportion of patients may be responsible for some of the
poorer outcomes in systemic sclerosis-PAH.
Right ventricular function
Despite pulmonary haemodynamics being more severe
in the idiopathic PAH group, Mathai et al. observed
significantly higher NT-proBNP levels in 55 systemic
sclerosis-PAH patients when compared with 43 idio-
pathic PAH patients [53]. This difference persisted even
when adjusting for renal function and age, and suggests a
poorer ability of the right ventricle to cope with increased
afterload. Overbeek et al. studied 13 systemic sclerosis-
PAH and 17 idiopathic PAH patients using the pump
function graph technique and demonstrated poorer right
ventricle contractility in the systemic sclerosis-PAH
group [54]. Tedford et al. performed pressure-volume
loops in 5 idiopathic PAH, 7 systemic sclerosis-PAH and
7 systemic sclerosis non-pulmonary hypertension
patients [55]. No significant difference in right ventricle
afterload as assessed by pulmonary vascular resistance
(PVR), compliance and arterial elastance (Ea) was
identified between the idiopathic PAH and systemic
sclerosis-PAH patients. Right ventricle contractility as
measured using end-systolic elastance (Ees) and the
coupling of right ventricle contractility with afterload
(Ees:Ea) were, however, poorer in systemic sclerosis-PAH
than in idiopathic PAH. Interestingly, Ees:Ea in systemic
sclerosis patients without pulmonary hypertension was
even more abnormal than in systemic sclerosis-PAH
patients. The underlying reason for these observations is
not clear. It is known that abnormal collagen deposition
is high in both ventricles in patients with systemic
sclerosis and no evidence of left heart disease or PAH
[56]. However, when Overbeek et al. examined right
ventricle samples for five systemic sclerosis-PAH and
nine idiopathic PAH patients they found no difference in
extent of interstitial fibrosis although there was a greater
inflammatory infiltrate in the systemic sclerosis-PAH
group [9].
Left heart disease
Hachulla et al. performed cardiac magnetic resonance
imaging in 52 patients with systemic sclerosis and
observed evidence of left ventricle systolic or diastolic
dysfunction in approximately ⅓ of cases, raising the
possibility that occult left heart diseasemay be responsible
for a proportion of diagnosed systemic sclerosis-PAH [57].
Fisher et al. observed evidence of left heart diastolic
dysfunction in approximately ⅓ of 50 patients fulfilling
diagnostic criteria for systemic sclerosis-PAH (with amean
age of 59) but only in approximately 10% of patients
diagnosed with idiopathic PAH (with a mean age of 48),
although its presence was not predictive of higher
mortality [49]. Fox et al. identified pulmonary hyperten-
sion in 53/107 systemic sclerosis patients who underwent
left and right heart catheterization [58]. Originally, 29/53
patients were given a diagnosis of PAH, but after fluid
challenge 11/29 (38%) were reclassified as pulmonary
hypertension secondary to left heart disease, which was in
keeping with radiological appearances of the left heart and
risk factors for left heart disease. A subsequent study
identified 207 patients fulfilling haemodynamic criteria
for PAH, 49% of whom had underlying CTD [59].
Following fluid challenge, 46/207 (22%) were reclassified
Table 2. Potential reasons for poorer outcome in SSc-PAH than in IPAH
Factor Evidence
Age Mean age of diagnosis of SSc-PAH ≈10 yrs > IPAH [25]. Age was independent prognostic factor in combined group of
SSc-PAH and IPAH [50].
Pulmonary vasculopathy Higher proportion of pulmonary venule involvement in SSc-PAH [10,51].
Right ventricle (RV) Reduced RV contractility assessed by pump function graph and pressure-volume loops in SSc-PAH [54,55]. Higher
NT-proBNP in SSc-PAH despite less severe pulmonary haemodynamics [53].
Left ventricle (LV) High prevalence of LV systolic and diastolic dysfunction in SSc [50,57]. ≈1/3 of patients fulfilling haemodynamic criteria for
SSc-PAH may have occult left heart disease based on response to fluid challenge and clinico-radiological characteristics
[58].
Interstitial lung disease (ILD) ILD common in SSc. Different registries have included varying degrees of ILD in SSc-PAH cohorts [29]. Response to PH
therapy in SSc in the presence of ILD appears poor [75].
Multisystem disease Coexisting renovascular and gastrointestinal disease including iron deficiency and malnutrition more common in SSc than
in general population.
Antibodies Exact role of SSc-associated autoantibodies (e.g. anticentromere) in pathogenesis of PAH and poorer prognosis compared
with idiopathic PAH not clear [76]. Elevated stimulating anti-endothelin receptor type A antibodies and anti-angiotensin
receptor type-1 antibodies in SSc-PAH compared with idiopathic PAH [17].
Abbreviations: IPAH, idiopathic pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; NT-proBNP,
N-terminal pro-brain natriuretic peptide; SSc, systemic sclerosis
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as pulmonary hypertension secondary to left heart disease.
It is, however, well recognized that elderly patients
fulfilling haemodynamic criteria for idiopathic PAH also
have a high prevalence of risk factors for left heart disease
and so it is unclear whether the potential misdiagnosis of
pulmonary hypertension with left heart disease as PAH is
more common in idiopathic PAH than in CTD-PAH [3].
Furthermore, the role of fluid challenge in the assessment
of pulmonary hypertension is not well defined, with the
positive predictive value for the presence of pulmonary
hypertension secondary to left heart disease being
unknown; hence it is not part of the diagnostic algorithm
in the most recent world pulmonary hypertension guide-
lines [1].
Interstitial lung disease
Interstitial lung disease (ILD) is common in patients
with systemic sclerosis and occurs more frequently in
diffuse than in limited cutaneous disease [60]. Defining
pulmonary hypertension in systemic sclerosis patients as
being isolated PAH rather than ILD-associated pulmon-
ary hypertension is not always straightforward. In the
absence of significant pulmonary hypertension, an
approach combining radiological assessment (limited
disease when the extent of ILD <10% and extensive
disease when the extent of disease >30%) and a
spirometric threshold of FVC 70% (when the extent of
ILD is estimated to be 10–30%) has been shown to
effectively identify patients with systemic sclerosis and
ILD with good and poor prognoses [46]. Whether this
approach also robustly differentiates systemic sclerosis-
PAH from ILD-associated pulmonary hypertension is
unclear. Several thresholds involving FVC or total lung
capacity (TLC) of 60 or 70% and/or varyingly-defined
minor/mild versus moderate/severe ILD have been
employed in different studies and it is very possible
that cohorts of “systemic sclerosis-PAH” in the literature
have been “contaminated” with a proportion of patients
who actually have ILD-associated pulmonary hyperten-
sion [29]. Several groups have demonstrated that ILD-
associated pulmonary hypertension in systemic sclerosis
is associated with a significantly poorer survival than
systemic sclerosis-PAH, despite similar pulmonary hae-
modynamics [26,61]. A retrospective study of 70
systemic sclerosis patients with ILD-associated pulmon-
ary hypertension was unable to demonstrate any clear
benefit from PAH-specific therapy. However, prospective
data are required and many centres have a low threshold
for PAH-specific therapy in this group of patients.
Iron deficiency
Iron deficiency has previously been shown to be
common in idiopathic PAH, occurring in up to 61% of
patients in the absence of overt anaemia in the majority
of cases, and is associated with poorer outcome [62].
Inappropriate elevation in serum hepcidin levels with
subsequent reduced iron gut absorption has been
postulated as a possible mechanism. Iron deficiency has
recently been reported as occurring in 46% of systemic
sclerosis-PAH and 16% of systemic sclerosis non-
pulmonary hypertension patients [63]. Both exercise
capacity and survival were reduced in those systemic
sclerosis-PAH patients with iron deficiency. Hepcidin
levels were found to be elevated while underlying
gastrointestinal angiodysplastic lesions may also predis-
pose iron deficiency in systemic sclerosis patients.
Although it is not clear whether iron deficiency is more
severe in systemic sclerosis-PAH, it is interesting to note
that haemoglobin levels were statistically significantly
lower in a recent study comparing 228 systemic sclerosis-
PAH patients and 279 idiopathic PAH patients [47].
Multisystem disease
Extra-cardiorespiratory manifestations of systemic sclero-
sis may impact on both morbidity and mortality.
Scleroderma renal crisis was previously a major cause of
mortality, although is now more treatable since the
availability of ACE inhibitors. Gastrointestinal involve-
ment can lead to severe nutritional deficiency.
Selected other CTD-PAH
The exact prevalence of pulmonary hypertension in
patients with SLE is unknown and estimates have ranged
from 2–43% depending on diagnostic methods used
[64,65]. Echocardiography-based studies are associated
with a significant risk of over-estimating pulmonary
pressures. Despite the prevalence of SLE being at least
3 times that of systemic sclerosis in the UK [66], the
number of SLE-associated PAH (SLE-PAH) patients in the
UK national registry was only 11% of the number of
systemic sclerosis-PAH patients, suggesting that the true
prevalence of PAH in patients with SLE is likely to be <1%
[26]. A recent prospective study of 245 patients with SLE
demonstrated pulmonary hypertension associated with
significant lung or left heart disease in 12 patients (5%),
but no cases of PAH were identified [67]. Patients with
SLE-PAH are younger than those with systemic sclerosis-
PAH, with higher pulmonary pressures and lower DLCO
[26,68]. Survival appears to be superior with 3-year
survival in the UK national registry of 74%, compared to
47% in systemic sclerosis-PAH [26]. Significant improve-
ments in PAH have been described in patients with SLE-
PAH (as well as some patients with mixed connective
tissue disease-associated PAH) treated with immunosup-
pression alone, although no good RCT data exist [69]. Our
approach is to treat active lupus aggressively and ensure
that all patients with SLE-PAH are adequately immuno-
suppressed. Antiphospholipid syndrome is a risk factor
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for the development of chronic thromboembolic pul-
monary hypertension and so, if SLE-PAH is suspected,
then particular attention to the exclusion of thromboem-
bolic disease is required [70].
Antisynthetase syndrome is characterised by myositis and
interstitial lung disease in the presence of anti-tRNA-
synthetase antibodies (most commonly Jo-1). A recent
French study calculated a right heart catheter-based
prevalence of pulmonary hypertension of 7.9% [71]. The
majority of patients had severe pre-capillary pulmonary
hypertension in the presence of significant coexisting ILD
while 3-year survival was 58%. PAH appears to be less
common in other forms of CTD, with an estimated
prevalence of 2% in mixed connective tissue disease [72],
while studies estimating the prevalence of PAH in other
forms of CTD (including Sjogren‘s syndrome and rheu-
matoid arthritis) have used echocardiography to calculate
systolic pulmonary arterial pressures with significant risk
of over-estimation [73,74].
Conclusion
Survival in systemic sclerosis-PAH remains poor. This
may be as a result of the underlying pulmonary arterial
vasculopathy and the poor ability of the right ventricle to
cope with increased afterload, together with the multi-
system nature of the condition including the involve-
ment ofmyocardium and lungs. Although early detection
of systemic sclerosis-PAH in patients is required, further
work todemonstrate adefinite impact on thenatural history
of the condition is needed. More extensive investigation of
the underlying molecular and genetic pathogenesis is
warranted, while specific trials of currently available and
novel PAH-specific therapies in systemic sclerosis-PAH are
urgently required.
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